Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders
May 02 2022 - 7:00AM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company developing the next generation of cancer and infectious
disease immunotherapies, today announced that it will report its
financial results for the first quarter ended March 31, 2022 and
provide recent clinical and corporate updates via a press release
on Thursday, May 5, 2022 at 4:05pm Eastern Time (ET).
To facilitate engagement with the company's shareholder base and
connections with its investors, Gritstone is partnering with Say
Technologies to enable shareholders to submit and upvote questions
through Say’s online portal, a selection of which will be answered
by Gritstone management via a post on the IR section of the
company’s website at
https://ir.gritstonebio.com/investors/events.
From 9:00am ET Tuesday, May 3 through 5:00pm ET Friday, May 6,
all shareholders can submit questions at the following link:
http://app.saytechnologies.com/gritstone-2022-q1
Gritstone will then post a response addressing select questions
after market close on Wednesday, May 11.
Shareholders can email support@saytechnologies.com for any
support inquiries.
About Gritstone Gritstone bio, Inc. (Nasdaq:
GRTS), a clinical-stage biotechnology company, is developing the
next generation of immunotherapies against multiple cancer types
and infectious diseases. Gritstone develops its products by
leveraging two key pillars—first, a proprietary artificial
intelligence-based platform, Gritstone EDGE™, which is designed to
predict antigens that are presented on the surface of cells, such
as tumor or virally-infected cells, that can be seen by the immune
system; and, second, the ability to develop and manufacture potent
immunotherapies utilizing these antigens to potentially drive the
patient’s immune system to specifically attack and destroy
disease-causing cells. The company’s lead oncology programs include
an individualized neoantigen-based immunotherapy, GRANITE, and an
“off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which
are being evaluated in clinical studies. Within its infectious
disease pipeline, Gritstone is advancing CORAL, a program
delivering T cell enhanced self-amplifying mRNA (samRNA) vaccine
candidates for COVID-19 that is supported by departments within the
National Institutes of Health (NIH), the Bill & Melinda Gates
Foundation, the Coalition for Epidemic Preparedness Innovations
(CEPI) and through a license agreement with La Jolla Institute for
Immunology. Additionally, the company has a global collaboration
for the development of a therapeutic HIV vaccine with Gilead
Sciences. For more information, please visit
www.gritstonebio.com.
Gritstone Forward-Looking StatementsThis
press release contains forward-looking statements, including, but
not limited to, statements related to the potential of Gritstone’s
therapeutic programs, the advancements in Gritstone’s ongoing
clinical trials and the timing of data announcements related to
ongoing clinical trials and the initiation of future clinical
trials. Such forward-looking statements involve substantial risks
and uncertainties that could cause Gritstone’s research and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the drug development process, including Gritstone’s programs’ early
stage of development, the process of designing and conducting
preclinical and clinical trials, the regulatory approval processes,
the timing of regulatory filings, the challenges associated with
manufacturing drug products, Gritstone’s ability to successfully
establish, protect and defend its intellectual property and other
matters that could affect the sufficiency of existing cash to fund
operations. Gritstone undertakes no obligation to update or revise
any forward-looking statements. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to the business of Gritstone in general, see
Gritstone’s most recent Annual Report on Form 10-K filed
on March 10, 2022 and Gritstone’s future reports to be
filed with the Securities and Exchange Commission. The
forward-looking statements in this press release are based on
information available to Gritstone as of the date hereof. Gritstone
disclaims any obligation to update any forward-looking statements,
except as required by law.
Gritstone ContactsMedia:Dan Budwick1AB(973)
271-6085dan@1abmedia.com
Investors:George E. MacDougallDirector, Investor Relations &
Corp CommsGritstone bio, Inc.ir@gritstone.com
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gritstone bio (NASDAQ:GRTS)
Historical Stock Chart
From Sep 2023 to Sep 2024